Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1753-1758

  Lehnerdt, Goetz F ^a   Franz, Peter ^a   Zaqoul, Anwar ^a   Schmitz, Klaus J ^a   Grehl, Sara ^b   Lang, Stephan ^a,b   Schmid, Kurt W ^a,b   Siffert, Winfried ^a,b   Jahnke, Klaus ^a,b   Frey, Ulrich H ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PARAFFIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HYPOPHARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; SEX DIFFERENCE; TUMOR LOCALIZATION;

ADULT; AGED; AMINO ACID SUBSTITUTION; CARCINOMA, SQUAMOUS CELL; CYSTEINE; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; THREONINE; TUMOR MARKERS, BIOLOGICAL;

EID: 41549120004     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1605     Document Type: Article

References (39)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Davies L, Welch HG. Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg 2006;135:451-7.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Chien CY, Su CY, Hwang CF, et al. Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx. Head Neck 2006;28:441-6.
5. Lang S, Wollenberg B, Dellian M, et al. [Clinical and epidemiological data of patients with malignomas of the head and neck]. Laryngorhinootologie 2002;81:499-508.
6. Ozer E, Grecula JC, Agrawal A, Rhoades CA, Young DC, Schuller DE. Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx. Laryngoscope 2006;116:607-12.
7. Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCCGORTEC). Int J Radiat Oncol Biol Phys 2006;64:983-94.
8. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose escalated hyperfractionated accelerated radiation therapy alone inlocally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005;23:1125-35.
9. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004;101:2222-9.
10. Baatenburg de Jong RJ, Hermans J, Molenaar J, Briaire JJ, le Cessie S. Prediction of survival in patients with head and neck cancer. Head Neck 2001;23:718-24.
11. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043- 55.
12. Furniss CS, McClean MD, Smith JF, et al. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 2007;120:2386-92.
13. Chin D, Boyle GM, Williams RM, et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005;113:789-97.
14. Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005;86:347-63.
15. Hitt R, Ciruelos E, Amador ML, et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005;41:453-60.
16. Magne N, Pivot X, Bensadoun RJ, et al. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer 2001;37:2169-77.
17. Smilek P, Dusek L, Vesely K, Rottenberg J, Kostrica R. Prognostic significance ofmitotic and apoptotic index and the DNA cytometry in head and neck cancer. Neoplasma 2005;52:199 -207.
18. Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol 2004;15:1319-29.
19. Frey UH, Eisenhardt A, Lummen G, et al. The T393C polymorphism of the Gas gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 2005;14:871-7.
20. Frey UH, Alakus H, Wohlschlaeger J, et al. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005;11:5071-7.
21. Frey UH, Lummen G, Jager T, et al. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006;12:759-63.
22. Frey UH, Nuckel H, Sellmann L, et al. The GNAS1 T393C polymorphismis associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 2006;12:5686-92.
23. Yang X, Lee FY, Sr., Wand GS. Increased expression of Gs(a) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 1997;11:1053-61.
24. Krumins AM, Barber R. Examination of the effects of increasing Gs protein on β2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol 1997;54:61-72.
25. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997;390:88-91.
26. Siffert W, Forster P, Jockel KH, et al. Worldwide ethnic distribution of the G protein β3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999;10:1921-30.
27. Cox DR, McCullagh P. Some aspects of analysis of covariance. Biometrics 1982;38:541-61.
28. Rudat V, Wannenmacher M. Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer. Semin Surg Oncol 2001;20:66-74.
29. Kulpa J, Stasik Z, Skolyszewski J, Wojcik E, Rychlik U, Pudelek K. Predictive value of SCC-Ag, CYFRA 21-1 and selected acute phase proteins in radiotherapy of pharyngeal and laryngeal cancer. A preliminary report. Neoplasma 2004;51:103-9.
30. Venkatesan TK, Kuropkat C, Caldarelli DD, et al. Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope 1999;109:1329-33.
31. Smilek P, Dusek L, Vesely K, Rottenberg J, Kostrica R. Correlation of expression of Ki-67, EGFR, c-erbB-2, MMP-9, p53, bcl-2, CD34 and cell cycle analysis with survival in head and neck squamous cell cancer. JExp Clin Cancer Res 2006;25:549-55.
32. Capon F, Allen MH, Ameen M, et al. A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet 2004;13:2361-8.
33. Duan J, Wainwright MS, Comeron JM, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003;12:205-16.
34. Tierney MJ, Medcalf RL. Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem 2001;276:13675-84.
35. Dumaz N, Light Y, Marais R. Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms. Mol Cell Biol 2002;22:3717- 28.
36. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006;66:9483-91.
37. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
38. Khan SM, Oliver RH, Dauffenbach LM, Yeh J. Depletion of Raf-1protooncogene by geldanamycin causes apoptosis in human luteinized granulosa cells. Fertil Steril 2000;74:359-65.
39. Yin X, Zhang H, Burrows F, Zhang L, Shores CG. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2005;11:3889-96.